Search research articles
Contact Us
Filters
Showing results (1191-1200 of 1,228) with videos related to
Page
of 123
Sort By:
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
June 17, 2025
Secondary Electron Hyperspectral Imaging of Carbons: New Insights and Good Practice Guide
James F Nohl, Nicholas T H Farr, Maria Rosaria Acocella, et al.
Prevention Science : the Official Journal of the Society for Prevention Research
|
August 17, 2022
Methodological Strategies for Prospective Harmonization of Studies: Application to 10 Distinct Outcomes Studies of Preventive Interventions Targeting Opioid Misuse
Ty A Ridenour, Gracelyn Cruden, Yang Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 21, 2023
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure
Chloe Orkin, Jonathan M Schapiro, Carlo F Perno, et al.
The Journal of Experimental Medicine
|
October 7, 2021
Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe
Guoxin Zhang, Zhen Dong, Ryan C Gimple, et al.
The Lancet. HIV
|
October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Hans Jaeger, Edgar T Overton, Gary Richmond, et al.
Lancet (London, England)
|
July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
AIDS (London, England)
|
March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
Amy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 2, 2021
Risk of COVID-19 Disease, Dialysis Unit Attributes, and Infection Control Strategy among London In-Center Hemodialysis Patients
Ben Caplin, Damien Ashby, Kieran McCafferty, et al.
Nature Cardiovascular Research
|
March 19, 2024
Disrupted propionate metabolism evokes transcriptional changes in the heart by increasing histone acetylation and propionylation
Kyung Chan Park, Nicholas T Crump, Niamh Louwman, et al.
Page
of 123
Search research articles
Search
Showing results (1191-1200 of 1,228) with videos related to
Sort By:
Page
of 123
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
June 17, 2025
Secondary Electron Hyperspectral Imaging of Carbons: New Insights and Good Practice Guide
James F Nohl, Nicholas T H Farr, Maria Rosaria Acocella, et al.
Prevention Science : the Official Journal of the Society for Prevention Research
|
August 17, 2022
Methodological Strategies for Prospective Harmonization of Studies: Application to 10 Distinct Outcomes Studies of Preventive Interventions Targeting Opioid Misuse
Ty A Ridenour, Gracelyn Cruden, Yang Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 21, 2023
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure
Chloe Orkin, Jonathan M Schapiro, Carlo F Perno, et al.
The Journal of Experimental Medicine
|
October 7, 2021
Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe
Guoxin Zhang, Zhen Dong, Ryan C Gimple, et al.
The Lancet. HIV
|
October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Hans Jaeger, Edgar T Overton, Gary Richmond, et al.
Lancet (London, England)
|
July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
AIDS (London, England)
|
March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
Amy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 2, 2021
Risk of COVID-19 Disease, Dialysis Unit Attributes, and Infection Control Strategy among London In-Center Hemodialysis Patients
Ben Caplin, Damien Ashby, Kieran McCafferty, et al.
Nature Cardiovascular Research
|
March 19, 2024
Disrupted propionate metabolism evokes transcriptional changes in the heart by increasing histone acetylation and propionylation
Kyung Chan Park, Nicholas T Crump, Niamh Louwman, et al.
Page
of 123